no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
1 |
Are toxicities of current nucleosides still a concern?
|
Vivancos, Maria J |
|
2018 |
5 |
4 |
p. e156-e157 |
article |
2 |
Commitment needed from South Africa's new president
|
The Lancet HIV, |
|
2018 |
5 |
4 |
p. e155 |
article |
3 |
Ending AIDS by 2030: catchy slogan or sincere goal?
|
Braithwaite, R Scott |
|
2018 |
5 |
4 |
p. e160-e161 |
article |
4 |
Indications for starting ART
|
Mussini, Cristina |
|
2018 |
5 |
4 |
p. e157-e158 |
article |
5 |
Migration and risk of HIV acquisition in Rakai, Uganda: a population-based cohort study
|
Olawore, Oluwasolape |
|
2018 |
5 |
4 |
p. e181-e189 |
article |
6 |
Migration patterns and HIV prevention in Uganda
|
Nöstlinger, Christiana |
|
2018 |
5 |
4 |
p. e158-e160 |
article |
7 |
Tenofovir alafenamide plus emtricitabine versus abacavir plus lamivudine for treatment of virologically suppressed HIV-1-infected adults: a randomised, double-blind, active-controlled, non-inferiority phase 3 trial
|
Winston, Alan |
|
2018 |
5 |
4 |
p. e162-e171 |
article |
8 |
The global Optima HIV allocative efficiency model: targeting resources in efforts to end AIDS
|
Kelly, Sherrie L |
|
2018 |
5 |
4 |
p. e190-e198 |
article |
9 |
Which HIV-infected adults with high CD4 T-cell counts benefit most from immediate initiation of antiretroviral therapy? A post-hoc subgroup analysis of the START trial
|
Molina, Jean-Michel |
|
2018 |
5 |
4 |
p. e172-e180 |
article |